Recombinant Human Wnt-2/sFRP-1 Complex Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11117-WN

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11117-WN-010
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Structure / Form

Non-covalent complex

Conjugate

Unconjugated

Applications

Bioactivity

View all Wnt-2 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human Wnt-2 protein
Human Wnt-2
(Ser26-Thr360)
Accession # P09544.1
Human sFRP-1
(Ser32-Lys314)
Accession # AAB70793.1
N-terminus C-terminus

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser26 (Wnt-2) & Ser32 (sFRP-1)

Predicted Molecular Mass

38 kDa (Wnt-2) & 33 kDa (sFRP-1)

SDS-PAGE

30-45 kDa, under reducing conditions.

Activity

Measured by its ability to activate Wnt induced TCF reporter activity in HEK293 human embryonic kidney cells.
The ED50 for this effect is 10.0-150 ng/mL.

Scientific Data Images for Recombinant Human Wnt-2/sFRP-1 Complex Protein, CF

Recombinant Human Wnt‑2/sFRP-1 Complex Bioactivity.

Recombinant Human Wnt-2/sFRP-1 (Catalog # 11117-WN) activates TCF reporter activity in HEK293 human embryonic kidney cells. The ED50 for this effect is 10.0-150 ng/mL.

Formulation, Preparation and Storage

11117-WN
Formulation Lyophilized from a 0.2 μm filtered solution in MOPS and NaCl with Trehalose.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Wnt-2

Wnt-2 is one of 19 vertebrate members of the Wingless-type MMTV integration site (Wnt) family of highly conserved cysteine-rich secreted glycoproteins that are important for normal developmental processes (1). Human Wnt-2 is a 35 kDa, secreted, glycosylated member of the Wnt family of developmental proteins. It is considered a class 1 Wnt based on its strong transforming activity on C57MG cells. Human Wnt-2 is synthesized as a 360 amino acid (aa) precursor that contains a 335 aa mature region. The mature region contains 24 cysteines and two potential N-linked glycosylation sites. Mature human Wnt-2 is 96% aa identical to mature mouse and rat Wnt-2. Wnt-2 is produced by mammary myoepithelial cells, endometrial epithelial cells, and breast fibroblasts (2, 3). Wnts bind to the cell surface Frizzled family receptors in conjunction with low-density lipoprotein receptor-related protein family receptors (LRP5 or 6) resulting in the stabilization of intracellular beta -catenin levels (4). As intracellular beta -catenin levels rise, beta -catenin binds to TCF/LEF transcription factors leading to expression of Wnt target genes (5). Wnt-2 is known to bind to sFRPs, a family of secreted molecules that contain an N-terminal cysteine-rich domain (CRD) highly similar to the CRDs of the Frizzled family receptors (6,7). More than one molecule of sFRP is suggested to participate in the interaction with each Wnt molecule (7). R&D Systems produces biologically active human Wnt-2 protein in a complex with human sFRP-1, and this Wnt-2/sFRP-1 complex is stable in the physiological buffer without detergent. Expression of Wnt-1, Wnt-2, E-cadherin, and beta-catenin is a common occurrence in non-small cell lung cancer (NSCLC) and is related to tumor histology and grade (8). Wnt-2 signaling is required for TGF-beta -mediated endothelial-to-mesenchymal transition (EndMT) of human aortic endothelial cells (HAECs), suggesting that Wnt-2 may contribute to atherosclerotic plaque development, and render Wnt-2 as a potential target for therapeutic intervention aiming at controlling atherosclerosis (9).

References

  1. Willert, K. and R. Nusse (2012) Cold Spring Harb. Perspect. Biol. 4:a007864.
  2. Van Ooyen, A. et al. (1985) EMBO J. 4:2905.
  3. Burrus, L.W. and A.P. McMahon (1995) Exp. Cell Res. 220:363.
  4. MacDonald, B.T. and X. He (2012) Cold Spring Harb. Perspect. Biol. 4:a007880.
  5. Korinek, V. et al. (1997) Science 275:1784.
  6. Dennis, S. et al. (1999) J. Cell Sci. 112:3815.
  7. Bafico, A. et al. (1999) J. Biol. Chem. 274:16180.
  8. Wrona, A. et al. (2021) Histochem. Cytochem. 69:711.
  9. Zhang, J. et al. (2021) Front. Cardiovasc. Med. 8:751720.

Long Name

Wingless-type MMTV Integration Site Family Member 2

Alternate Names

INT1L1, IRP, Wnt2

Entrez Gene IDs

7472 (Human); 22413 (Mouse); 114487 (Rat)

Gene Symbol

WNT2

Additional Wnt-2 Products

Product Documents for Recombinant Human Wnt-2/sFRP-1 Complex Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human Wnt-2/sFRP-1 Complex Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.